Kiichiro Ninomiya

机构：Okayama Shoka University, Okayama University, Okayama University Hospital · ORCID：0000-0002-2134-2865

发表论文 213 篇 · 总被引 1938 次 · h-index 22

代表论文

Phase III study of multidisciplinary therapy combining local ablative therapy with immune-checkpoint inhibitors for patients with synchronous oligometastatic NSCLC (J-OLIGO: WJOG20924L). (2026 · Journal of Clinical Oncology · 被引 1)
Supplementary Figure 4 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC (2026)
Supplementary Figure 2 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC (2026)
Supplementary Figure 3 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC (2026)
Supplementary Figure 1 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC (2026)
Supplementary Figure 6 from Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC (2026)